NDC 58657-454 Me Naphos Mb Hyo 1

Urinary Antiseptic Antispasmodic

NDC Product Code 58657-454

NDC CODE: 58657-454

Proprietary Name: Me Naphos Mb Hyo 1 What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Urinary Antiseptic Antispasmodic What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Product Characteristics

Shape: OVAL (C48345)
10 MM
Score: 1

NDC Code Structure

  • 58657 - Method Pharmaceuticals

NDC 58657-454-01

Package Description: 100 TABLET in 1 BOTTLE

NDC Product Information

Me Naphos Mb Hyo 1 with NDC 58657-454 is a a human prescription drug product labeled by Method Pharmaceuticals. The generic name of Me Naphos Mb Hyo 1 is urinary antiseptic antispasmodic. The product's dosage form is tablet and is administered via oral form.

Labeler Name: Method Pharmaceuticals

Dosage Form: Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Me Naphos Mb Hyo 1 Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • METHENAMINE 81.6 mg/1

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • FD&C BLUE NO. 1 (UNII: H3R47K3TBD)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Oxidation-Reduction Activity - [MoA] (Mechanism of Action)
  • Oxidation-Reduction Agent - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Method Pharmaceuticals
Labeler Code: 58657
Marketing Category: UNAPPROVED DRUG OTHER - What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 12-01-2015 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Me Naphos Mb Hyo 1 Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


Each tablet contains:
Methenamine, USP ................................. 81.6 mg

Monobasic Sodium Phosphate, USP ......... 40.8 mg

Methylene Blue ....................................... 10.8 mg

Hyoscyamine Sulfate ............................... 0.12 mg

Inactive Ingredients Include:


Cellulose, Mannitol, Croscarmellose Sodium, Magnesium

Stearate, FD&C Blue #1
HYOSCYAMINE SULFATE is an alkaloid of belladonna.

Exists as a white crystalline powder. Affected by light It

is very soluble in water; freely soluble in alcohol;

practically insoluble in ether.

METHENAMINE exists as colorless, lustrous crystals or

white crystalline powder. Its solutions are alkaline to

litmus. Freely soluble in water; soluble in alcohol and in

METHYLENE BLUE exists as dark green crystals. It is

soluble in water and in chloroform; sparingly soluble in


crystalline powder. Its solutions are acidic to litmus. It is

freely soluble in water and practically insoluble in

This product is not an Orange Book (OB) rated

product, therefore all prescriptions using this

product shall be pursuant to state statutes as

applicable. There are no claims of bioequivalence

or therapeutic equivalence.

Clinical Pharmacology

HYOSCYAMINE is a parasympatholytic which relaxes

smooth muscles and thus produces an antispasmodic

effect. It is well absorbed from the gastrointestinal tract

and is rapidly distributed throughout body tissues. Most

is excreted in the urine within 12 hours, 13% to 50%

being unchanged.

Its biotransformation is hepatic. Its protein binding is

METHENAMINE degrades in an acidic urine environment

releasing formaldehyde which provides bactericidal or

bacteriostatic action. It is well absorbed from the

gastrointestinal tract. 70% to 90% reaches the urine

unchanged at which point it is hydrolyzed if the urine is

acidic. Within 24 hours it is almost completely (90%)

excreted; of this amount at pH 5, approximately 20% is

formaldehyde. Protein binding: some formaldehyde is

bound to substances in the urine and surrounding

tissues. Methenamine is freely distributed to body tissue

and fluids but is not clinically significant as it does not

hydrolyze at pH greater than 6.8.
METHYLENE BLUE possesses weak antiseptic properties.

It is well absorbed in the gastrointestinal tract and is

rapidly reduced to leukomethylene blue which is

stabilized in some combination form in the urine. 75%

is excreted unchanged.

acid pH in the urine necessary for the degradation of


Indication And Usage

ME/NaPhos/MB/Hyo 1 Tablets is indicated for the

treatment of symptoms of irritative voiding. Indicated

for the relief of local symptoms, such as hypermotility

which accompany lower urinary tract infections and as

antispasmodic. Indicated for the relief of urinary tract

symptoms caused by diagnostic procedures.


Do not exceed recommended dosage. If rapid pulse,

dizziness, or blurring of vision occurs
discontinue use



(Pregnancy Category C)

hyoscyamine and methenamine cross the placenta.

Studies have not been done in animals or humans. It is

not known whether
ME/NaPhos/MB/Hyo 1Tablets cause fetal harm when administered to a

pregnant woman or can affect reproduction capacity.
ME/NaPhos/MB/Hyo 1 Tablets should be given to

a pregnant woman only if clearly needed.


Problems in humans have not been documented;

however, methenamine and traces of hyoscyamine are

excreted in breast milk.

Prolonged Use

There have been no studies to establish the safety of

prolonged use in humans. No known long-term animal

studies have been performed to evaluate carcinogenic



Infants and young children are especially susceptible to

the toxic effect of the belladonna alkaloids.


Use with caution in elderly patients as they may respond

to usual doses of hyoscyamine with excitement,

agitation, drowsiness, or confusion.

Drug Interactions

Because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the

absorption of other oral medications during concurrent

use such as: urinary alkalizers; thiazide diuretics (may

cause the urine to become alkaline reducing the

effectiveness of methenamine by inhibiting its

conversion to formaldehyde); antimuscarinics

(concurrent use may intensify antimuscarinic effects of

hyoscyamine because of secondary antimuscarinic

activities of these medications); antacids/antidiarrheals

(may reduce absorption of hyoscyamine, concurrent use

with antacids may cause urine to become alkaline

reducing effectiveness of methenamine by inhibiting its

conversion to formaldehyde) doses of these medications

should be spaced 1 hour apart from doses of

hyoscyamine; antimyasthenics (concurrent use with

hyoscyamine may further reduce intestinal motility);

ketoconazole (patients should be advised to take this

combination at least 2 hours after ketoconazole);

monoamine oxidase (MAO) Inhibitors (concurrent use

may intensify antimuscarinic side effects, opioid

(narcotic) analgesics may result in increased risk of

severe constipation); sulfonamides (these drugs may

precipitate with formaldehyde in the urine, increasing

the danger of crystalluria).

Patients should be advised that the urine may become

blue to blue green and the feces may be discolored as a

result of the excretion of methylene blue.

Adverse Reactions

Cardiovascular – rapid pulse, flushing
Central Nervous System – blurred vision, dizziness

Respiratory – shortness of breath or troubled

Genitourinary – difficulty micturition, acute urinary

Gastrointestinal – dry mouth, nausea/vomiting

Drug Abuse And Dependence

A dependence on the use of
ME/NaPhos/MB/Hyo 1Tablets has not been reported and due to the nature of

its ingredients, abuse of
ME/NaPhos/MB/Hyo 1

is not expected.


Emesis or gastric lavage. Slow intravenous

administration of physostigmine in doses of 1 mg to

4 mg (0.5 mg to 1 mg in children), repeated as needed

in one to two hours to reverse severe antimuscarinic

symptoms. Administration of small doses of diazepam to

control excitement and seizures. Artificial respiration

with oxygen if needed for respiratory depression.

Adequate hydration. Symptomatic treatment as


Dosage And Administration

One tablet orally 4 times per day followed by liberal

fluid intake.
Older Children
Dosage must be individualized by physician. Not

recommended for use in children up to 6 years of age.

How Supplied

ME/NaPhos/MB/Hyo 1 Tablets are light blue to

blue, oval, biconvex tablets debossed with

"M455" with scoreline on one side and plain on

the other side. Supplied in bottles of 100 tablets

(NDC 58657-454-01).

Other Safety Information

Store at 25° C (77° F); excursions permitted to 15° C to

30° C (59° F to 86° F) [See USP Controlled

Room Temperature]. Keep container tightly closed.
Distributed By: Method Pharmaceuticals, LLC

Arlington, TX 76006
Rev. Date: 01/2016

General Precautions

DIRECTIONS: 1 Tablet 4 times daily followed by liberal fluid intake, or

as directed by a physician.
Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to

86° F) [See USP Controlled Room Temperature]. Protect from moisture or

direct sunlight.
NOTE: Patient should be advised that urine will be colored blue while

taking this medication.
PHARMACIST: Preserve and dispense in tight-light resistant container as

defined in the USP.
KEEP THIS AND ALL MEDICINES OUT OF THE REACH OFCHILDREN.Tamper evident by heat seal under cap. Do not use if there is

evidence of tampering.
To report an adverse event, please contact Method

Pharmaceuticals, LLC at (877) 250-3427.

* Please review the disclaimer below.